At a glance
- Originator Egis Pharmaceuticals
- Class Antidepressants; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder; Parkinson's disease
Most Recent Events
- 24 Aug 2001 No-Development-Reported for Depression in Hungary (Unknown route)
- 24 Aug 2001 No-Development-Reported for Parkinson's disease in Hungary (Unknown route)
- 03 Jan 1997 Preclinical development for Depression in Hungary (Unknown route)